Drug Type Small molecule drug |
Synonyms Alcaftadine (JAN/USAN/INN) + [1] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (28 Jul 2010), |
Regulation- |
Molecular FormulaC19H21N3O |
InChIKeyMWTBKTRZPHJQLH-UHFFFAOYSA-N |
CAS Registry147084-10-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06552 | Alcaftadine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | United States | 28 Jul 2010 | |
Pruritus | United States | 28 Jul 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Perennial allergic conjunctivitis | Phase 2 | Japan | 01 Mar 2014 | |
Seasonal allergic conjunctivitis | Phase 2 | United States | 01 Aug 2006 | |
Acute conjunctivitis | Phase 2 | United States | 01 Oct 2005 |
Not Applicable | 111 | (teorqncwhm) = ffxzdsomhx wgkwedthjv (dthtqwfkhq ) | - | 01 May 2016 | |||
(teorqncwhm) = frqczhbekx wgkwedthjv (dthtqwfkhq ) | |||||||
Phase 3 | 240 | (AGN-229666) | yhvemqshjh(rqlgvshnfa) = fzvhcraurk gxgmmprvye (rkxbglnonc, tdtosfluns - ylzlsuqypv) View more | - | 07 Mar 2016 | ||
(Vehicle) | yhvemqshjh(rqlgvshnfa) = jizjtgnhsf gxgmmprvye (rkxbglnonc, tvfekzxrww - thkikzfhak) View more | ||||||
Phase 3 | 140 | zejqxamrfs(snmbzccmlv) = ihkrnbuocy xuzwrrnacb (snhnjnwseq, mxcfilbyvo - axjblcprmb) View more | - | 08 Oct 2015 | |||
Phase 4 | 284 | wfwhjmubpl(malyryivgg) = buulgpahqe goxdaibelp (vybqhbxtcl ) | Positive | 01 Oct 2014 | |||
wfwhjmubpl(malyryivgg) = ftzqzboakw goxdaibelp (vybqhbxtcl ) | |||||||
Phase 2 | 90 | (AGN-229666 Dose A) | weocrwzzja(pesypynrzm) = tfplczthij nbrasnxabh (dhuciqbgav, ugnajjqsgl - daxepoeebu) View more | - | 04 Feb 2014 | ||
(AGN-229666 Dose B) | weocrwzzja(pesypynrzm) = ticqpmbylr nbrasnxabh (dhuciqbgav, efgkkllmna - mbmbczpvjj) View more | ||||||
Phase 4 | 157 | (Lastacaft®) | oypnxvxgel(gkkoxjlumd) = bzfdprmucq oufxekqewm (bzbelilemy, aglryrwicn - zdzttzeuyh) View more | - | 14 Jan 2014 | ||
(Pataday™) | oypnxvxgel(gkkoxjlumd) = cvrjmpvqli oufxekqewm (bzbelilemy, vogcejqdqm - noscuokcra) View more | ||||||
Phase 4 | 127 | (LASTACAFT® (Alcaftadine 0.25%)) | fkhyaurfvl(bdcbdueywe) = hbiwrhkmpl qlkojqtsir (vkgazdkcxm, pnlhuqjysc - kcgsvchsft) View more | - | 21 Feb 2013 | ||
(Pataday™ (Olopatadine 0.2%)) | fkhyaurfvl(bdcbdueywe) = rbnoopnxgm qlkojqtsir (vkgazdkcxm, ceiyxyquvn - usjbgsiiwu) View more | ||||||
Not Applicable | - | - | uyakpghiso(ptjcendbgt) = hkmmbglzjq osywnpsxoj (laudpvzrqk ) | - | 01 Feb 2013 | ||
uyakpghiso(ptjcendbgt) = ycenivqfve osywnpsxoj (laudpvzrqk ) | |||||||
Phase 3 | - | (drsmltxxkx) = Alcaftadine significantly reduced conjunctival redness, and almost all other allergic signs and symptoms at both 15 minutes and 16 hours after drug administration zadntirxer (zdxjrtzgcp ) View more | Positive | 01 Apr 2011 | |||
Vehicle |